The active type of
coagulation factor X (
factor Xa) activates various cell-types through
protease-activated receptor 2 (PAR2). We previously reported that
a factor Xa inhibitor could suppress Thy-1
nephritis. Considering that
fibrin deposition is observed in
diabetic nephropathy as well as in
glomerulonephritis, this study examined the roles of the coagulation pathway and
factor Xa in the development of
diabetic nephropathy using type 2 diabetic model mice. Diabetic (db/db) and normoglycemic (m+/m+) mice were immunohistochemically evaluated for their expression/deposition of PAR2,
transforming growth factor (TGF)-β,
fibrin, extracellular matrix (ECM)
proteins, and CD31 at week 20. Significantly greater numbers of PAR2-positive cells and larger amounts of
fibronectin, and
collagen IV depositions were observed in the glomeruli of db/db mice than those in m+/m+ mice. Next, expression of PAR2 versus deposition of
collagen IV and
fibronectin was compared between week 20 and week 30, and the number of PAR2-positive cells in the glomeruli decreased in contrast with the increased accumulation of ECM
proteins. In an intervention study,
fondaparinux,
a factor Xa inhibitor, was subcutaneously administered for ten weeks from week 10 to 20.
Fondaparinux treatment significantly suppressed urinary
protein, glomerular
hypertrophy,
fibrin deposition, expression of
connective tissue growth factor, and ECM
proteins deposition together with CD31-positive capillaries. These results suggest that coagulation pathway and glomerular PAR2 expression are upregulated in the early phase of diabetes, together with the increase of profibrotic
cytokines expression, ECM
proteins deposition and CD-31-positive vessels.
Factor Xa inhibition may ameliorate glomerular neoangiogenesis and ECM accumulation in
diabetic nephropathy.